

Supplemental online content for:

Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms


Taymeyah Al-Toubah, MPH; Eleonora Pelle, MD; Tiffany Valone, PA-C; Mintallah Haider, MD; and
Jonathan R. Strosberg, MD

J Natl Compr Canc Netw 2022;20(1):29–36


eFigure 1: Progression-Free and Overall Survival

eFigure 2: Progression-Free and Overall Survival by Primary Site of Disease

eTable 1: Patient Demographics



eFigure 1. (A) Progression-free and **(B)** overall survival.



eFigure 2. (A) Progression-free and **(B)** overall survival by primary site of disease.

eTable 1. Patient Demographics	
Characteristic	n (%)
Sex	
Male	252 (54.55)
Female	210 (45.45)
Age, y	
16–29	11 (2.38)
30–44	55 (11.90)
45–59	170 (36.80)
60–74	181 (39.18)
≥75	45 (9.74)
Number of prior lines	
0	132 (28.57)
1	187 (40.48)
2	78 (16.88)
3	46 (9.96)
4	7 (1.52)
5	6 (1.30)
6	2 (0.43)
≥7	4 (0.86)